Eden Research plc - Change of Adviser
("Eden" or "Company")
Appointment of Nominated Adviser and Broker
For further information contact:
| || |
01285 359 555
| || |
Cenkos Securities (Nominated advisor and broker)
020 7397 8900
| || |
| || |
Powerscourt (Financial PR)
020 7250 1446
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of
Mevalone has been authorised for sale in
Eden was admitted to trading on AIM on
For more information about Eden, please visit: www.edenresearch.com.
This information is provided by RNS, the news service of the
Quick facts: Eden Research plc
Market Cap: £12.95 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE